PEGylated PLGA nanoparticles: unlocking advanced strategies for cancer therapy.

IF 27.7 1区医学 Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY

Molecular Cancer Pub Date : 2025-07-24 DOI:10.1186/s12943-025-02410-x

Prashant Kesharwani,Vishal Kumar,Khang Wen Goh,Garima Gupta,Abdulrhman Alsayari,Shadma Wahab,Amirhossein Sahebkar

{"title":"PEGylated PLGA nanoparticles: unlocking advanced strategies for cancer therapy.","authors":"Prashant Kesharwani,Vishal Kumar,Khang Wen Goh,Garima Gupta,Abdulrhman Alsayari,Shadma Wahab,Amirhossein Sahebkar","doi":"10.1186/s12943-025-02410-x","DOIUrl":null,"url":null,"abstract":"Poly(lactic-co-glycolic acid) (PLGA) is a widely utilized biodegradable and biocompatible polymer in drug delivery systems, particularly for encapsulating drug molecules with poor solubility and permeability. PLGA nanoparticles, composed of polylactic acid (PLA) and polyglycolic acid (PGA), offer tunable properties such as controlled degradation rates and drug release kinetics. The PEGylation of PLGA nanoparticles results in the formation of a polyethylene glycol (PEG) corona on their surface, which enhances systemic circulation by reducing opsonization and immune system recognition. This extended circulation time increases the likelihood of nanoparticles reaching the target site, a crucial advantage in cancer therapy, as it allows for reduced dosage frequency while improving therapeutic efficacy. Furthermore, surface functionalization with targeting ligands enables selective delivery to specific cells or organs via ligand-receptor interactions, facilitating enhanced cellular uptake and intracellular drug release. This review provides a comprehensive analysis of PEGylated PLGA nanoparticles in cancer diagnosis and therapy, highlighting recent advancements, current challenges, and future perspectives in their clinical translation.","PeriodicalId":19000,"journal":{"name":"Molecular Cancer","volume":"113 1","pages":"205"},"PeriodicalIF":27.7000,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12943-025-02410-x","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Poly(lactic-co-glycolic acid) (PLGA) is a widely utilized biodegradable and biocompatible polymer in drug delivery systems, particularly for encapsulating drug molecules with poor solubility and permeability. PLGA nanoparticles, composed of polylactic acid (PLA) and polyglycolic acid (PGA), offer tunable properties such as controlled degradation rates and drug release kinetics. The PEGylation of PLGA nanoparticles results in the formation of a polyethylene glycol (PEG) corona on their surface, which enhances systemic circulation by reducing opsonization and immune system recognition. This extended circulation time increases the likelihood of nanoparticles reaching the target site, a crucial advantage in cancer therapy, as it allows for reduced dosage frequency while improving therapeutic efficacy. Furthermore, surface functionalization with targeting ligands enables selective delivery to specific cells or organs via ligand-receptor interactions, facilitating enhanced cellular uptake and intracellular drug release. This review provides a comprehensive analysis of PEGylated PLGA nanoparticles in cancer diagnosis and therapy, highlighting recent advancements, current challenges, and future perspectives in their clinical translation.

查看原文本刊更多论文

聚乙二醇化PLGA纳米颗粒：解锁癌症治疗的先进策略。

聚乳酸-羟基乙酸（PLGA）是一种广泛应用于药物递送系统的可生物降解和生物相容性聚合物，特别是用于包封溶解度和渗透性较差的药物分子。由聚乳酸（PLA）和聚乙醇酸（PGA）组成的聚乳酸纳米颗粒具有可调节的性能，如可控制的降解速率和药物释放动力学。聚乙二醇化的聚乙二醇纳米颗粒导致其表面形成聚乙二醇（PEG）电晕，通过减少光化和免疫系统识别来促进体循环。这种延长的循环时间增加了纳米颗粒到达目标部位的可能性，这是癌症治疗的一个关键优势，因为它可以减少给药频率，同时提高治疗效果。此外，靶向配体的表面功能化可以通过配体与受体的相互作用选择性地递送到特定的细胞或器官，促进细胞摄取和细胞内药物释放。这篇综述全面分析了聚乙二醇化PLGA纳米颗粒在癌症诊断和治疗中的应用，强调了其临床转化的最新进展、当前挑战和未来前景。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Molecular Cancer 医学-生化与分子生物学

CiteScore

54.90

自引率

2.70%

发文量

224

审稿时长

2 months

期刊介绍： Molecular Cancer is a platform that encourages the exchange of ideas and discoveries in the field of cancer research, particularly focusing on the molecular aspects. Our goal is to facilitate discussions and provide insights into various areas of cancer and related biomedical science. We welcome articles from basic, translational, and clinical research that contribute to the advancement of understanding, prevention, diagnosis, and treatment of cancer. The scope of topics covered in Molecular Cancer is diverse and inclusive. These include, but are not limited to, cell and tumor biology, angiogenesis, utilizing animal models, understanding metastasis, exploring cancer antigens and the immune response, investigating cellular signaling and molecular biology, examining epidemiology, genetic and molecular profiling of cancer, identifying molecular targets, studying cancer stem cells, exploring DNA damage and repair mechanisms, analyzing cell cycle regulation, investigating apoptosis, exploring molecular virology, and evaluating vaccine and antibody-based cancer therapies. Molecular Cancer serves as an important platform for sharing exciting discoveries in cancer-related research. It offers an unparalleled opportunity to communicate information to both specialists and the general public. The online presence of Molecular Cancer enables immediate publication of accepted articles and facilitates the presentation of large datasets and supplementary information. This ensures that new research is efficiently and rapidly disseminated to the scientific community.